Regulation and action of angiogenic factors in the primate ovary

Archives of Medical Research

Volumn 32, Issue 6, 2001, Pages 567-575

  Stouffer, Richard L ^a   Martínez Chequer, Juan Carlos ^a   Molskness, Theodore A ^a   Xu, Fuhua ^a   Hazzard, Timothy M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Angiopoietin; Anti angiogenic drugs; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD31 ANTIGEN; CHORIONIC GONADOTROPIN; ENDOTHELIN; FIBROBLAST GROWTH FACTOR 2; FOLLITROPIN; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; LUTEINIZING HORMONE; MESSENGER RNA; NEUROPILIN; NEUROPILIN 1; NEUROPILIN 2; PROSTAGLANDIN; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE TIE1; RECEPTOR TYROSINE KINASE TIE2; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR R1; VASCULAR ENDOTHELIAL GROWTH FACTOR R2; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CORPUS LUTEUM FUNCTION; FEMALE FERTILITY; IMMUNOCYTOCHEMISTRY; MENSTRUAL CYCLE; NONHUMAN; OVARY CYCLE; OVARY FOLLICLE DEVELOPMENT; OVULATION; OXYGEN TENSION; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHORIONIC GONADOTROPIN; CORPUS LUTEUM; CYCLOHEXANES; ENDOTHELIAL GROWTH FACTORS; FATTY ACIDS, UNSATURATED; FEMALE; GONADAL STEROID HORMONES; GROWTH SUBSTANCES; LUTEINIZING HORMONE; LYMPHOKINES; MENSTRUAL CYCLE; MUTAGENESIS, SITE-DIRECTED; NEOVASCULARIZATION, PHYSIOLOGIC; OVARIAN FOLLICLE; OVARY; OVULATION; OXYGEN; PRIMATES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CELL SURFACE; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RIBONUCLEASE, PANCREATIC; SESQUITERPENES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035676788     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(01)00323-X     Document Type: Review

References (52)

1. Signaling vascular morphogenesis and maintenance
2. Angiogenesis in cancer and other diseases
3. Vascular morphogenesis in the ovary
4. Angiogenesis in ovarian follicular and luteal development
5. Growth and development of the corpus luteum
6. Cyclic changes of vasculature and vascular phenotypes in normal human ovaries
7. A quantitative study of changes in the human corpus luteum microvasculature during the menstrual cycle
8. Proliferation of microvascular endothelial cells in the primate corpus luteum during the menstrual cycle and simulated early pregnancy
9. Mechanisms of angiogenesis and arteriogenesis
10. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
11. Luteal function: The estrous cycle and early pregnancy
12. Intraovarian regulation of luteolysis
13. Current status of antiangiogenic factors
14. Corpus luteum angiogenic factor is related to fibroblast growth factor
15. Vascular-specific growth factors and blood vessel formation
16. The biology of vascular endothelial growth factor
17. Vascular endothelial growth factor (VEGF) and its receptors
18. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
19. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165
20. Receptors for collapsin/semaphorins
21. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants
22. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
23. Differential expression and regulation of the vascular endothelial growth factor receptors neuropilin-1 and neuropilin-2 in rat uterus
24. First evidence for expression of neuropilin-1 (NP-1), an isoform-specific vascular endothelial growth factor (VEGF) coreceptor, in the primate corpus luteum
25. Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval
26. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy
27. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy
28. Angiogenesis in the human corpus luteum: Localization and changes in angiopoietins, Tie-2, and vascular endothelial growth factor messenger ribonucleic acid
29. Changes in expression of vascular endothelial growth factor (VEGF), angiopoietin (Ang)-1 and Ang-2 in the macaque corpus luteum during the menstrual cycle
30. The vascular character of ovarian follicular granulosa cells: Phenotypic and functional evidence for an endothelial-like cell population
31. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction
32. Regulation of vascular endothelial growth factor (VEGF) production by gonadotropin and oxygen in nonluteinized and luteinized granulosa cells of rhesus monkeys
33. Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by macaque granulosa cells from pre- and periovulatory follicles
34. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary
35. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells
36. Endometrial angiogenesis
37. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium
38. Insulin and insulin-like growth factors (IGFS) promote vascular endothelial growth factor (VEGF) secretion by macaque granulosa cells from preovulatory follicles
39. Regulation of vascular-endothelial growth factor (VEGF) by insulin, IGF-I and IGF-II in luteinized human granulosa cells: A role in the pathogenesis of ovarian hyperstimulation syndrome (OHSS)?
40. CIP/WAF for endothelial cell growth arrest
41. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470
42. The effect of the angiogenesis inhibitor TNP-470 on luteal establishment and function in the primate
43. Injection of an angiogenesis inhibitor (TNP-470) into the periovulatory follicle causes luteal dysfunction in rhesus monkeys
44. Anti-nidatory effect of vaginally administered fumagillin in the rhesus monkey
45. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
46. Placental vascular morphogenesis
47. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor
48. Injection of vascular endothelial growth factor receptor 1 (VEGFR1) into the periovulatory follicle causes luteal dysfunction in rhesus monkeys
49. Lymphatic and blood vasculature of the forming corpus luteum
50. Evidence for the presence of angiogenin in human follicular fluid and the up-regulation of its production by human chorionic gonadotropin and hypoxia
51. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
52. Vascular endothelial growth factor transgenic mice exhibit reduced male fertility and placental rejection